Cytotoxic effects of combined treatment with Ukrain and methotrexate in vitro studies
Keywords:
Ukrain, metotreksat, badania in vitroAbstract
In in vitro studies of this work the cytotoxicity of drug Ukrain, methotrexate and their combination in green monkey kidney (GMK) cells culture was assessed using ready-made kit Cytotoxicity Detection Kit LDH. For assay of cell viability MTT test was used. It was found that 6 or 12 hrs of simultaneous incubation of GMK cells with drug Ukrain (50 μmol/l) with MTX (5.5 or 16.5 μmol/l) did not affect cytotoxicity in the LDH test. The significant increase of the cytotoxicity was found after 12 hrs. incubation GMK cells with Ukrain (150 μmol/l) and MTX (5.5 μmol/l). Likewise, in the MTT assay the greatest decrease in the cells viability was found after GMK cells incubation with Ukrain (150 μmol/l) and MTX (5.5 μmol/l). The results suggest the adverse effect of combined application of both drugs in these concentrations on the GMK cells viability.
References
1. Aschhoff B.: Retrospective study of Ukrain treatment in 203 patients with advanced-stage tumors. Drugs Exp. Clin. Res., 26, 249¬, 2000.
2. Bangert C.A., Costner M.I.: Methotrexate in dermatology. Dermatol. Ther., 20, 216, 2007.
3. Blower P. et al.: Drug – drug interactions on oncology: Why are they important and can they be minimized?, Crit Rev Oncol. Hematol., 55, 117, 2005.
4. Gansauge F. et al.: NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial. Langenbecks Arch. Surg. 386, 570, 2002.
5. Green M.R., Chamberlain M.C.: Renal dysfunction during and after high-dose methotrexate. Cancer Chemother. Pharmacol., 63, 599, 2009.
6. Izdebska M., Piątkowska-Chmiel I., Jagiełło-Wójtowicz E.: Ocena cytotoksycznego działania metotreksatu i leku Ukrain w badaniach in vitro. W: II Ogólnopolskie Sympozjum ,,Nowoczesne techniki badawcze w ocenie jakości produktów leczniczych.” Lublin, 24-25 września 2009, P-82, s. 109.
7. Jagiełło-Wójtowicz E. et al. : Ukrain (NSC-631570) in experimental and clinical studies: a review. Drugs Exp. Clin. Res., 24, 213, 1998.
8. Habermehl D. et al.: Proapoptotic activity of Ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathway. BMC Cancer, 6, 14, 2006.
9. Kimura E. et al.: Methotrexate differentially affects growth of suspension and adherent cells. Int. J. Biochem. Cell Biol., 36, 814, 2004.
10. Liepins A. et al.: Induction of bimodal programmed cell death in malignant cells by the derivative Ukrain (NSC-631570). Drugs Exp. Clin. Res., 22, 73, 1996.
11. Lohninger A., Hamler F.: Chelidonium majus L. (Ukrain) in the treatment of cancer patients. Drugs Exp. Clin. Res., 18, 73, 1992.
12. Nowicky J.W. et al.: Influence of Ukrain on DNA, RNA and protein synthesis in malignant cells. Drugs Exp. Clin. Res., 22, 81, 1996.
13. Nowicky J.W. et al.: Ukrain both as an anticancer and immunoregulatory agent. Drugs Exp. Clin. Res., 18, 51, 1992.
14. Roublevskaia I.N. et al.: Induced apoptosis in human prostate cancer cell line LNCaP by Ukrain. Drugs Exp. Clin. Res., 26, 141, 2000.
15. Strang A., Pullar T.: Methotrexate toxicity induced by acute renal failure. J. R. Soc. Med., 97, 536, 2004.
16. Uglyanitsa K.N. et al.: Ukrain: A novel antitumor drug. Drugs Exp. Clin. Res., 26, 341, 2000.
Downloads
Published
Issue
Section
License
Copyright (c) 2011 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
